[ORGANIZATION]
Tudriqev
Featured in 2 tracked stories · first seen
Situations
Replimune melanoma therapy FDA approval
3 clusters · 18 sources · last updated
Latest: FDA approves new oncolytic viral therapy for anti‑PD‑1‑refractory melanoma
Following the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee vote of 10‑3 in late July 2026, the agency granted accelerated approval on 6 August 2026 to Replimune’s oncolytic herpes‑virus therapy RP1, marke